Revealing the role of the benzyloxy pharmacophore in the design of a new class of monoamine oxidase-B inhibitors

Arch Pharm (Weinheim). 2022 Aug;355(8):e2200084. doi: 10.1002/ardp.202200084. Epub 2022 May 13.

Abstract

The conceptual layout of monoamine oxidase (MAO) inhibitors has been modified to explore their potential biological application in the case of neurological disorders for the time being. The current review article is an effort to display the summation of innovative conceptual prospects of MAO inhibitors and their intriguing chemistry and bioactivity. Based on this scenario, we emphasize the pivotal role of the benzyloxy moiety attached to scaffolds like oxadiazolones, indolalkylamines, safinamide, caffeine, benzofurans, α-tetralones, β-nitrostyrene, benzoquinones, coumarins, indoles, chromones, and chromanone analogs, while acting as an MAO inhibitor.

Keywords: MAO-A; MAO-B; benzyloxy pharmacophore; neurological disorders; structure-activity relationships.

Publication types

  • Review

MeSH terms

  • Chromones / pharmacology
  • Coumarins
  • Dopamine Agents
  • Monoamine Oxidase Inhibitors* / pharmacology
  • Monoamine Oxidase* / metabolism
  • Structure-Activity Relationship

Substances

  • Chromones
  • Coumarins
  • Dopamine Agents
  • Monoamine Oxidase Inhibitors
  • Monoamine Oxidase